CRIS curis.com Return on Sales by Gross Profit

CRIS (Curis, Inc.) - company brandmark

Curis, Inc. aims to expand the application of emavusertib to capture a larger share of the oncology market. These ambitions are supported by partnerships with Roche and Genentech in the development of targeted therapies. Analyzing the gross profit margin, this chart from GURU.Markets shows the value holding at 94.60. However, high capital expenditure and regulatory complexities create risks of share dilution for investors.

CRIS (Curis, Inc.) Gross Margin history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Curis Corp (CRIS)

- current quotes and average value forecast:
Summary company analysis:CRIS - Curis, Inc.
Brand item of Curis Inc.

For long-term risk management, it is critical to track gross margin dynamics, which measure the portion of revenue remaining after deducting direct production costs. An analysis of the gross profit-to-revenue ratio for Curis, Inc. (CRIS) confirms the potential for high markups due to the patent protection of targeted drugs, providing the company with a sustainable competitive advantage and fundamental business strength in cancer therapy.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit